Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Case 25: - The woman whose kidneys could not handle lithium
Published online by Cambridge University Press: 03 April 2024
Book contents
- Case Studies: Stahl’s Essential Psychopharmacology
- Case Studies: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- Contributors
- List of icons
- Abbreviations
- Case 1: Usage of esketamine spray for treatment-resistant major depressive disorder (MDD)
- Case 2: The man who is confused about his identity
- Case 3: Propane, shattered glass, and parasites
- Case 4: Hit by a car
- Case 5: Caring for the whole person
- Case 6: The man whom clozapine (Clozaril) could not touch
- Case 7: Where did her period go?
- Case 8: To dopamine or not to dopamine, that is the question
- Case 9: The one that came out of nowhere
- Case 10: Darth Vaper strikes again
- Case 11: First-time Mom’s struggle with postpartum post-traumatic stress disorder (PTSD)
- Case 12: Why so down?
- Case 13: It’s confusing, isn’t it?
- Case 14: The adolescent who just can’t stay awake
- Case 15: The lady with bipolar disorder (BP), borderline personality disorder (BPD), and myasthenia gravis (MG)
- Case 16: Spending money does not make a bipolar diagnosis
- Case 17: Pain makes me anxious, and anxiety gives me pain
- Case 18: The woman who couldn’t focus
- Case 19: The gentleman with sudden onset of akathisia on clozapine (Clozaril)
- Case 20: The pregnancy blues
- Case 21: The menopause blues
- Case 22: The lady who felt “funny” on the medication
- Case 23: Two ladies with bruises
- Case 24: The lady who was afraid for her kids
- Case 25: The woman whose kidneys could not handle lithium
- Case 26: The gentleman who was sober and could not focus
- Case 27: When the music does not stop
- Case 28: The man who tried to get it right
- Index of drug names
- Index of case studies
- References
Summary
At what level of kidney failure should you likely discontinue lithium (Eskalith)?
Keywords
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential Psychopharmacology , pp. 421 - 440Publisher: Cambridge University PressPrint publication year: 2024
References
Aiken, CB, Orr, C. Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature. Psychiatry (Edgmont) 2010; 7:27–32Google Scholar
Dutta, S, Reed, RC. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug: as shown by once-daily divalproex-ER. Clin Drug Investig 2006; 26:681–90CrossRefGoogle ScholarPubMed
Dutta, S, Reed, RC, O’Dea, RF. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets – clinical implications. Ann Pharmacother 2006; 40:619–25CrossRefGoogle ScholarPubMed
Gitlin, MJ. Antidepressants in bipolar depression: an enduring controversy. Int J Bipolar Disord 2018; 6:25CrossRefGoogle ScholarPubMed
Gupta, S, Kripalani, M, Khastgir, U, et al. Management of the renal adverse effects of lithium. Adv Psychiatr Treat 2013; 19:457–66CrossRefGoogle Scholar
Hayes, JF, Marston, L, Walters, K, et al. Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry 2016; 15:53–8CrossRefGoogle ScholarPubMed
Hong, JSW, Atkinson, LZ, Al-Juffali, N, et al. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: systematic review, meta-analysis, and rationale. Mol Psychiatry 2022; 27:1339–49CrossRefGoogle ScholarPubMed
Kang, MG, Qian, H, Keramatian, K, et al. Lithium vs valproate in the maintenance treatment of bipolar I disorder: a post-hoc analysis of a randomized double-blind placebo-controlled trial. Aust N Z J Psychiatry 2020; 54:298–307CrossRefGoogle ScholarPubMed
Kessing, LV, Hellmund, G, Geddes, JR, et al. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011; 199:57–63CrossRefGoogle ScholarPubMed
Kverno, K, Beauvois, L, Dudley-Brown, S. Lamotrigine rash. Nurse Pract 2018; 43:48–51CrossRefGoogle ScholarPubMed
Mathews, M, Gratz, S, Adetunji, B, et al. Antipsychotic-induced movement disorders: evaluation and treatment. Psychiatry (Edgmont) 2005; 2:36–41Google ScholarPubMed
Mowla, A, Boostani, S, Ehsaei, Z. Comparing lithium with valproate for clinical and social status of bipolar disorder patients in inter-episode interval: a retrospective comparative study. J Neurol Res 2020; 10:226–30CrossRefGoogle Scholar
Pigott, K, Galizia, I, Vasudev, K, et al. Topiramate for acute affective episodes in bipolar disorder in adults. Cochrane Database Syst Rev 2016; 9:CD003384-CD003384Google ScholarPubMed
Sachs, GS. Strategies for improving treatment of bipolar disorder: integration of measurement and management. Acta Psychiatr Scand Suppl 2004; 7–17CrossRefGoogle Scholar